CASI Pharmaceuticals, Inc. (CASIF)
OTCMKTS · Delayed Price · Currency is USD
0.2100
0.00 (0.00%)
At close: Mar 9, 2026

CASI Pharmaceuticals Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 2021FY 2020
Period Ending
Sep '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
26.8528.5433.8843.1130.1715.14
Revenue Growth (YoY)
21.72%-15.77%-21.41%42.89%99.25%-
Cost of Revenue
-31.76-17.39-13.83-15.8312.569.51
Gross Profit
9.6111.1520.0527.2817.615.63
Selling, General & Admin
-103.47-41.44-41.84-37.7838.4127.48
Research & Development
-19.24-8.92-9.86-1620.9829.3
Other Operating Expenses
0.54-0.99-6.57-9.910.391.64
Operating Income
-45.1-39.62-25.08-34.03-41.52-52.78
Interest Income
0.260.540.630.19--
Interest Expense
-0.92-0.87-0.02-0.06--
Other Non-Operating Income (Expense)
-1.381.88-1.83-3.535.354.4
Total Non-Operating Income (Expense)
-2.041.55-1.21-3.45.354.4
Pretax Income
-47.13-38.07-26.29-37.43-35.84-47.51
Provision for Income Taxes
---0.081.98--
Net Income
-47.13-39.26-26.96-41.01-36.65-48.29
Minority Interest in Earnings
-2.25-1.190.65-0.090.810.78
Net Income to Common
-47.13-39.26-26.96-41.01-36.65-48.29
Shares Outstanding (Basic)
151513141411
Shares Outstanding (Diluted)
151513141411
Shares Change (YoY)
15.80%15.96%-2.10%0.27%23.23%-
EPS (Basic)
-3.04-2.53-2.02-3.01-2.69-4.37
EPS (Diluted)
-3.04-2.53-2.02-3.01-2.69-4.37
Free Cash Flow
--29.45-20.17-26.7-35.79-27.39
Free Cash Flow Per Share
---1.51-1.96-2.63-2.48
Gross Margin
35.80%39.06%59.19%63.28%58.38%37.20%
Operating Margin
-167.98%-138.84%-74.03%-78.95%-137.62%-348.60%
Profit Margin
-183.93%-137.57%-77.51%-93.39%-118.81%-313.79%
FCF Margin
--103.19%-59.54%-61.94%-118.63%-180.87%
EBITDA
-45.1-36.17-20.35-30.42-38.42-49.55
EBITDA Margin
-167.98%-126.75%-60.07%-70.57%-127.36%-327.26%
EBIT
-45.1-39.62-25.08-34.03-41.52-52.78
EBIT Margin
-167.98%-138.84%-74.03%-78.95%-137.62%-348.60%
Effective Tax Rate
-0.00%0.31%-5.29%0.00%0.00%
Updated Sep 30, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.